← Return to Breast cancer patient also with osteoporosis: AI, Prolia and Reclast

Discussion
Comment receiving replies
@windyshores

@gently I worry that the effects of sclerostin suppression are not adequately studied. Most studies are on cardiovascular effects and those studies showed no difference in risk between Evenity and placebo, and small difference (but significant) between Evenity and alendronate (which might be because alendronate has a positive effect).

But sclerositin is throughout the body, including central nervous system, joints/cartilage....I am having long complicated weird dreams that have no connection to daytime concerns. In some ways that concerns me more than joint pain.

For breast cancer, I was told Reclast , and my cousin is on Zometa- both zoledronic acid. I wonder if doctors are hesitant to prescribe bone builders like Forteo, Tymlos, Evenity because they can't be given when metastasis is possible. Maybe in early cancer this is still an issue if/when cells are still wandering around-???

Jump to this post


Replies to "@gently I worry that the effects of sclerostin suppression are not adequately studied. Most studies are..."


At least the restricted plasma level of the bone-derived protein, SOST, is correlated with reduced brain Aβ load in a cognitively unimpaired older adults. https://www.ncbi.nlm.nih.gov/pmc/issues/427415/
My concern is cardiac valves.
I think the reluctance to prescribe is entirely the evidence from rats predisposed to cancer. The registery that allowed the elimination of the black box would have to have been skewed, who would prescribe and who would take the risk. Mostly white women of our age. But no mechanism of action has been proposed.
The internet is rife with the now retracted warnings. I wish at least the universities would delete the disproven information from their sites.
I spoke with an endocrinologist last week who was not aware of the change for Forteo and skeptical of its existence.
I would so love to hear your dreams.